-
Press Release
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
-
Press Release
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
-
Press Release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
-
Press Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
-
Story
What's next in Neuroscience drug discovery -
Press Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Press Release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
-
Press Release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025